[{"id":"63d174f5-1045-41f8-a030-f399abb4d1dd","acronym":"NCI-2016-00073","url":"https://clinicaltrials.gov/study/NCT02697344","created_at":"2021-01-18T13:10:03.223Z","updated_at":"2024-07-02T16:35:25.022Z","phase":"Phase 1","brief_title":"Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma","source_id_and_acronym":"NCT02697344 - NCI-2016-00073","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • CRBN • MAPK1","pipe":" | ","alterations":" BCL2 expression • CRBN expression","tags":["BCL2 • CRBN • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • CRBN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 10/26/2018","primary_completion_date":" 10/26/2018","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2023-12-28"},{"id":"2a514802-0bd5-42d1-abc9-294d1a4f3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT06133088","created_at":"2023-11-15T19:16:06.349Z","updated_at":"2024-07-02T16:35:29.099Z","phase":"Phase 2","brief_title":"Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.","source_id_and_acronym":"NCT06133088","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" CDK6 • LRPPRC","pipe":"","alterations":" ","tags":["CDK6 • LRPPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • R-(-)-gossypol (AT 101)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-11-15"},{"id":"759ba1b6-e6e6-4f22-81f3-e0016eb2b1d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01633541","created_at":"2021-01-18T07:01:11.806Z","updated_at":"2024-07-02T16:35:42.408Z","phase":"Phase 2","brief_title":"Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer","source_id_and_acronym":"NCT01633541","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 11/06/2021","primary_completion_date":" 11/06/2021","study_txt":" Completion: 11/06/2021","study_completion_date":" 11/06/2021","last_update_posted":"2023-07-20"},{"id":"3a95cb99-a207-4584-bf34-fd1b90df2dbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00540722","created_at":"2021-01-18T01:57:56.081Z","updated_at":"2024-07-02T16:37:18.969Z","phase":"Phase 2","brief_title":"Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme","source_id_and_acronym":"NCT00540722","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-08-11"}]